Shares of CareDx turned positive after Craig Hallum said the Centers for Medicare and Medicaid Services’ announcement today that transplant patients can continue to access blood tests is a positive for the company. The shares are up 31c to $10.03 in afternoon trading after trading lower earlier in the day.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CDNA:
- CareDx Unveils Updated Financial Health and Strategy Presentation
- Natera announces next phase of CareDx patent infringement litigation
- CDNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Jury rules in favor of Natera in patent infringement lawsuit against CareDx
- CareDx found to have not infringed on one Natera patent, infringed on another
